98%
921
2 minutes
20
Background: Thermal ablation is one of the first-line treatments for patients with hepatocellular carcinoma (HCC) with a massive potential of long-term cure. However, it is disadvantaged by the relatively high rate of postoperative recurrence. In this study, a comparison was performed in the prognostic performance between albumin-bilirubin (ALBI) grade and Child-Pugh (C-P) grade for those HCC patients undergoing thermal ablation.
Methods: A total of 467 patients undergoing thermal ablation as the initial therapy were recruited and retrospectively analyzed. Then, an investigation was carried out into the prognostic values of overall survival (OS) and recurrence free survival (RFS) through ALBI grade and C-P score, separately. Besides, propensity-score matching (PSM) was performed to adjust the significantly different patient characteristics for ALBI grade based on C-P A patients.
Results: In the multivariate analysis, both ALBI and C-P grades were treated as independent prognostic factors for OS. Cox multivariate analysis was conducted to reveal that the independent risk factors for postoperative HCC recurrence included ALBI grade 2-3, multiple tumors, tumor size ≥2 cm, and age ≥65 years. Following PSM (1:1), both ALBI-1 and ALBI-2 groups were found to be well matched in all of the parameters involved. Depending on the ALBI grade (113 ALBI-1 113 ALBI-2), C-P A patients were reclassified into two risk groups for OS (P=0.0058) and RFS (P=0.012), respectively.
Conclusions: The conventional C-P classification, despite its necessity, is less effective in assessing preoperative liver dysfunction for HCC patients and subjected to some limitations. Characterized by simplicity and objectivity, the ALBI grade has demonstrated its greater prognostic value than C-P grade for HCC patients who underwent thermal ablation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459596 | PMC |
http://dx.doi.org/10.21037/tcr-22-244 | DOI Listing |
Radiol Phys Technol
September 2025
Division of Health Sciences, Graduate School of Medical Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa, Ishikawa, 920-0942, Japan.
This study evaluated whether temporal changes from the dynamic late phase to the hepatobiliary phase using gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid supported liver tumor classification. A total of 147 patients with 165 lesions (hepatocellular carcinoma [HCC], metastases, and hemangiomas) underwent 3.0 T MRI.
View Article and Find Full Text PDFActa Med Philipp
July 2025
Division of Internal Medicine, National Kidney and Transplant Institute, Quezon City, Philippines.
Background And Objective: Patients with liver cirrhosis have an increased risk for poor postoperative outcomes after non-hepatic surgery, with liver dysfunction being the most important predictor of poor outcomes. This study aims to determine the association of the albumin-bilirubin (ALBI) grade, aspartate aminotransferase-platelet ratio index (APRI) score, and ALBI-APRI score with postoperative outcomes among cirrhotic patients who have undergone non-hepatic surgery.
Methods: This was a retrospective cohort study involving 34 patients.
In Vivo
August 2025
Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Türkiye.
Background/aim: Cholangiocarcinoma (CCA) is the second most frequently occurring primary malignant tumor of the liver, characterized by poor survival due to late diagnosis and limited treatment options. The albumin-bilirubin (ALBI) and platelet-ALBI (PALBI) scores, which reflect liver function and inflammation, have emerged as potential prognostic markers in hepatocellular carcinoma (HCC). Their prognostic significance in CCA, however, remains less established.
View Article and Find Full Text PDFCancer Med
September 2025
Department of Gastroenterology and Hepatology, Institute of Science Tokyo, Tokyo, Japan.
Background/aim: The global aging population includes an increasing number of elderly patients with hepatocellular carcinoma (HCC). This study aimed to clarify the real-world outcomes, prognostic factors, and appropriate administration indicators for immunotherapy in elderly HCC patients.
Methods: This retrospective multicenter study analyzed 286 patients with unresectable HCC who received first-line immunotherapy (atezolizumab-bevacizumab or durvalumab-tremelimumab) between November 2020 and January 2024.
BMC Cancer
August 2025
Division of Gastroenterology, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.
Background: The factors associated with extrahepatic recurrence (EHR) after curative resection for hepatocellular carcinoma (HCC) have rarely been investigated. This study examined the pre- and postoperative predictors of EHR after curative resection in HCC patients over a ten-year follow-up period.
Methods: A retrospective review was conducted on treatment-naïve HCC patients who underwent curative resection between 2004 and 2019 at four tertiary hospitals in South Korea.